Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas

A phase I trial of ABT-888 (veliparib), a poly(ADP-ribose) polymerase (PARP inhibitor), in combination with topotecan, a topoisomerase I–targeted agent, was performed to determine maximum tolerated dose (MTD), safety, pharmacokinetics, and pharmacodynamics of the combination in patients with refract...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Kummar, Shivaani, Chen, Alice, Ji, Jiuping, Zhang, Yiping, Reid, Joel M., Ames, Matthew, Jia, Lee, Weil, Marcie, Speranza, Giovanna, Murgo, Anthony J., Kinders, Robert, Wang, Lihua, Parchment, Ralph E., Carter, John, Stotler, Howard, Rubinstein, Larry, Hollingshead, Melinda, Melillo, Giovanni, Pommier, Yves, Bonner, William, Tomaszewski, Joseph E., Doroshow, James H.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2011
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3166628/
https://ncbi.nlm.nih.gov/pubmed/21795476
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-11-1227
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi